A Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Sacramento, California
- Aurora, Colorado
- Tampa, Florida
- Chicago, Illinois
- Iowa City, Iowa
- Fairway, Kansas
- Fairway, Kansas
- Kansas City, Kansas
- Kansas City, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Boston, Massachusetts
- Minneapolis, Minnesota
- Saint Louis, Missouri
- Durham, North Carolina
- Durham, North Carolina
- Cincinnati, Ohio
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- South Brisbane, Queensland
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Sofia,
- Calgary, Alberta
- Vancouver, British Columbia
- London, Ontario
- Montreal, Quebec
- Genova,
- Genova,
- Genova,
- Genova,
- Genova,
- Rome,
- Rome,
- Rome,
- Rome,
- Rome,
- Rome,
- Hyogo,
- Tokyo,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Warszawa,
- Liverpool,
- Liverpool,
- London,
- London,
- Newcastle upon Tyne,
- Newcastle upon Tyne,
- Newcastle-upon-Tyne,
- Chongqing, Chongqing
- Chongqing, Chongqing
- Fuzhou, Fujian
- Beijing,
- Beijing,
- Shanghai,
- Shanghai,
- Shanghai,
- Salt Lake City, Utah
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Durham, North Carolina
- Durham, North Carolina
- Durham, North Carolina
- Durham, North Carolina
- Durham, North Carolina
- Durham, North Carolina
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- Roma,
- Jerusalem,
- Petach Tikvah,
- Esplugues de Llobregat, Barcelona
- Barcelona,
- Valencia,
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy | ||||||
Official Title ICMJE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ||||||
Brief Summary | The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year. | ||||||
Detailed Description | The study will assess the efficacy of PF-06939926 gene therapy on ambulatory function while also monitoring its safety. Approximately 99 boys with DMD will be enrolled and randomly assigned to one of two groups: approximately two thirds will be in Cohort 1 and receive gene therapy at the start of the study; approximately one third will be in Cohort 2 and receive placebo at the start of the study and receive gene therapy after one year, as long as it remains safe to do so. The treatment (PF-06939926 gene therapy or placebo) will be given as an intravenous infusion lasting up to 2 hours. The study includes boys who are at least 4 years old and less than 8 years old (including 7 year olds up until their 8th birthday). All boys will need to be on a daily dose of glucocorticoids (prednisone, prednisolone, or deflazacort) for at least 3 months prior to enrolling and to stay on daily glucocorticoids for the first 2 years of the study. All boys will need to be negative for neutralizing antibodies against AAV9, as measured by the test done for the study as part of screening. The primary outcome of the study will be assessed at 52 weeks. All participants will be followed in the study for 5 years after treatment with gene therapy. The study medication, all medical tests associated with the study, and the visits to the study sites are free of charge. Participants will also be supported for travel costs associated with study visits. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Parallel up to the measurement of the primary outcome at Week 52. At the beginning of study Year 2 participants who were originally assigned to placebo will have the opportunity to receive PF-06939926. All participants will be followed for 5 years following treatment with PF-06939926. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: The study will be quadruple blind. Primary Purpose: Treatment
| ||||||
Condition ICMJE | Duchenne Muscular Dystrophy | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 99 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Estimated Study Completion Date ICMJE | September 29, 2027 | ||||||
Estimated Primary Completion Date | September 29, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Key inclusion criteria:
Key exclusion criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 4 Years to 7 Years (Child) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Israel, Italy, Spain | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT04281485 | ||||||
Other Study ID Numbers ICMJE | C3391003 2019-002921-31 ( EudraCT Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |